Edition:
United States

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

504.00INR
25 May 2017
Change (% chg)

-- (--)
Prev Close
Rs504.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,200,948
52-wk High
Rs621.25
52-wk Low
Rs457.45

Latest Key Developments (Source: Significant Developments)

Cipla exec expects to file for approval of more than 20 products in the U.S. in FY18
7:55am EDT 

May 25 (Reuters) - Cipla Ltd : :Cipla exec says remodelling Cipla Biotec towards an in-licensing structure.Cipla exec says plan to be very active on in-licensing opportunities.Cipla exec says expects to file for approval of more than 20 products in the U.S. in FY18.Cipla exec says memorandum of understanding signed for a South Africa plant signed last year is on hold.Cipla exec says expects volatility in India market in coming months due to GST.  Full Article

Cipla U.S. arm signs worldwide licensing deal with MEDRx
Thursday, 6 Apr 2017 03:22am EDT 

Cipla Ltd : Says Cipla USA enters into collaboration with Medrx . Medrx is eligible to receive up to USD 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments . Medrx will also receive tiered royalties on the net sales of commercialized licensed products .Worldwide licensing agreement (except for east asia) signed for development, commercialize of mrx-4tzt, a tizanidine1 patch for spasticity.  Full Article

Cipla Ltd says co does not import for sale or sell Tadalafil tables in US market
Friday, 24 Mar 2017 12:34am EDT 

Cipla Ltd : Cipla Ltd clarifies on news item "USFDA issued import alert on Cipla's Tadalafil drug made at Bhagwanpur unit" . Says co does not directly or indirectly import for sale or sell Tadalafil tables in US market . Says co not authorised any party to import for sale or sell Tadalafil tables in US market . Co is not associated with referenced import alert of Tadalafil product or its source at Bhagwanpur site for US market .The event has no impact on Cipla.  Full Article

Ascendis says to acquire Cipla Agrimed & Cipla Vet for 375 mln rand
Monday, 6 Mar 2017 12:05am EST 

Ascendis Health Limited : Acquisition Of 100 pct Of Cipla Agrimed Proprietary Limited And Cipla Vet Proprietary Limited . Deal for consideration of r375 million . Purchase consideration of between r250 million and r500 million will be settled out of existing cash and facilities . A deferred payment of r50 million which will be settled in cash on 2 July 2018. . Effective date for proposed transaction is expected to be 1 April 2017 .Combined profit after tax of acquisitions was r31 million for period ended 31 March 2016.  Full Article

Cipla Ltd Dec-qtr consol profit up about 44 pct
Wednesday, 8 Feb 2017 06:33am EST 

Cipla Ltd : Consol Dec quarter net profit 3.75 billion rupees . Consol Dec quarter net sales 35.50 billion rupees . Consol net profit in Dec quarter last year was 2.61 billion rupees as per Ind-AS; consol net sales was 30.70 billion rupees .Consensus forecast for Dec quarter consol net profit was 3.70 billion rupees.  Full Article

Cipla says unit entered definitive agreement to sell stake in Four M Propack
Wednesday, 18 Jan 2017 07:05am EST 

Cipla Ltd : Says unit entered in to a definitive agreement to sell its 100% equity stake in Four M Propack, India .Cipla ltd says deal for a consideration of INR 135 million.  Full Article

Cipla's flagship product Sereflo gets final nod from UK MHRA
Friday, 23 Dec 2016 04:28am EST 

Cipla Ltd : Cipla’s flagship product Sereflo receives final approval from UK MHRA . Cipla’s sereflo will be launched in the UK through a partner in the coming weeks .Product used for treatment of asthma.  Full Article

Cipla gets EIR from USFDA for its Indore facility
Wednesday, 12 Oct 2016 07:47am EDT 

Cipla Ltd :Cipla receives EIR from the US FDA for its Indore facility.  Full Article

Cipla Ltd exec says co expects about 200 mln rupees of impact from FDC ban, NLEM in Q2
Friday, 12 Aug 2016 08:51am EDT 

Cipla Ltd : Cipla's Samina Vaziralli says "the family is completely committed", "absolutely no prospect" of selling the company . Exec says expects about 200 million rupees of impact from FDC ban and NLEM in Q2 . Further company coverage [CIPL.NS] ((Bangalore.newsroom@thomsonreuters.com)).  Full Article

Cipla Ltd appoints Umang Vohra as MD, global CEO
Friday, 12 Aug 2016 06:11am EDT 

Cipla Ltd : Accepted resignation of Subhanu Saxena as MD and global CEO wef August 31 . Appointed Umang Vohra as MD and global CEO .  Full Article

More From Around the Web

India's Cipla lowers bio drugs investment, sharpens focus on respiratory

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products, the company's chief executive said on Thursday.